Crizotinib, a MET inhibitor, inhibits growth, migration, and invasion of breast cancer cells in vitro and synergizes with chemotherapeutic agents

References

• PolyakKBreast cancer: origins and evolutionJ Clin Invest2007117113155316317975657
   PubMed Web of Science ®Google Scholar
• HonJDSinghBSahinABreast cancer molecular subtypes: from TNBC to QNBCAm J Cancer Res2016691864187227725895
   PubMed Web of Science ®Google Scholar
• GoldhirschAWoodWCCoatesASPanel MembersStrategies for subtypes – dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011Ann Oncol20112281736174721709140
   PubMed Web of Science ®Google Scholar
• SorlieTTibshiraniRParkerJRepeated observation of breast tumor subtypes in independent gene expression data setsProc Natl Acad Sci U S A2003100148418842312829800
   PubMed Web of Science ®Google Scholar
• PerouCMSorlieTEisenMBMolecular portraits of human breast tumoursNature2000406679774775210963602
   PubMed Web of Science ®Google Scholar
• TranBBedardPLLuminal-B breast cancer and novel therapeutic targetsBreast Cancer Res201113622122217398
   PubMed Web of Science ®Google Scholar
• SchmidtMKoelblHAdjuvant chemotherapy in early breast cancerMinerva Ginecol2012641536522334231
   PubMedGoogle Scholar
• SwainSMChemotherapy: updates and new perspectivesOncologist201015suppl 5817
   PubMedGoogle Scholar
• AndrechekERMullerWJTyrosine kinase signalling in breast cancer: tyrosine kinase-mediated signal transduction in transgenic mouse models of human breast cancerBreast Cancer Res20002321121611250712
   PubMedGoogle Scholar
• HynesNETyrosine kinase signalling in breast cancerBreast Cancer Res20002315415711250704
   PubMed Web of Science ®Google Scholar
• RhoOKimDJKiguchiKDigiovanniJGrowth factor signaling pathways as targets for prevention of epithelial carcinogenesisMol Carcinog201150426427920648549
   PubMedGoogle Scholar
• SattlerMSalgiaRc-Met and hepatocyte growth factor: potential as novel targets in cancer therapyCurr Oncol Rep20079210210817288874
   PubMedGoogle Scholar
• SierraJRTsaoMSc-MET as a potential therapeutic target and biomarker in cancerTher Adv Med Oncol201131 supplS21S3522128285
   PubMedGoogle Scholar
• CecchiFRabeDCBottaroDPTargeting the HGF/Met signalling pathway in cancerEur J Cancer20104671260127020303741
   PubMed Web of Science ®Google Scholar
• GranitoAGuidettiEGramantieriLc-MET receptor tyrosine kinase as a molecular target in advanced hepatocellular carcinomaJ Hepatocell Carcinoma20152293827508192
   PubMed Web of Science ®Google Scholar
• AwazuYNakamuraKMizutaniAA novel inhibitor of c-Met and VEGF receptor tyrosine kinases with a broad spectrum of in vivo antitumor activitiesMol Cancer Ther201312691392423548264
   PubMedGoogle Scholar
• Gonzalez-AnguloAMChenHKaruturiMSFrequency of mesenchymal-epithelial transition factor gene (MET) and the catalytic subunit of phosphoinositide-3-kinase (PIK3CA) copy number elevation and correlation with outcome in patients with early stage breast cancerCancer2013119171522736407
   PubMed Web of Science ®Google Scholar
• InancMOzkanMKaracaHCytokeratin 5/6, c-Met expressions, and PTEN loss prognostic indicators in triple-negative breast cancerMed Oncol201431180124326984
   PubMed Web of Science ®Google Scholar
• PonzoMGLesurfRPetkiewiczSMet induces mammary tumors with diverse histologies and is associated with poor outcome and human basal breast cancerProc Natl Acad Sci U S A200910631129031290819617568
   PubMedGoogle Scholar
• GraveelCRDeGrootJDSuYMet induces diverse mammary carcinomas in mice and is associated with human basal breast cancerProc Natl Acad Sci U S A200910631129091291419567831
   PubMedGoogle Scholar
• ZhangZWangJJiDFunctional genetic approach identifies MET, HER3, IGF1R, INSR pathways as determinants of lapatinib unresponsiveness in HER2-positive gastric cancerClin Cancer Res201420174559457324973425
   PubMed Web of Science ®Google Scholar
• MatteucciEBendinelliPDesiderioMANuclear localization of active HGF receptor Met in aggressive MDA-MB231 breast carcinoma cellsCarcinogenesis200930693794519357348
   PubMedGoogle Scholar
• GotteMKerstingCRadkeIKieselLWulfingPAn expression signature of syndecan-1 (CD138), E-cadherin and c-met is associated with factors of angiogenesis and lymphangiogenesis in ductal breast carcinoma in situBreast Cancer Res200791R817244359
   PubMedGoogle Scholar
• DuYYamaguchiHWeiYBlocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitorsNat Med201622219420126779812
   PubMed Web of Science ®Google Scholar
• Gozdzik-SpychalskaJSzyszka-BarthKSpychalskiLC-MET inhibitors in the treatment of lung cancerCurr Treat Options Oncol201415467068225266653
   PubMedGoogle Scholar
• ScagliottiGVNovelloSvon PawelJThe emerging role of MET/HGF inhibitors in oncologyCancer Treat Rev201339779380123453860
   PubMed Web of Science ®Google Scholar
• BellonSFKaplan-LefkoPYangYc-Met inhibitors with novel binding mode show activity against several hereditary papillary renal cell carcinoma-related mutationsJ Biol Chem200828352675268318055465
   PubMed Web of Science ®Google Scholar
• SolomonBJMokTKimDWPROFILE 1014 InvestigatorsFirst-line crizotinib versus chemotherapy in ALK-positive lung cancerN Engl J Med2014371232167217725470694
   PubMed Web of Science ®Google Scholar
• CappuzzoFMoro-SibilotDGautschiOManagement of crizotinib therapy for ALK-rearranged non-small cell lung carcinoma: an expert consensusLung Cancer2015872899525576294
   PubMed Web of Science ®Google Scholar
• KazandjianDBlumenthalGMChenHYFDA approval summary: crizotinib for the treatment of metastatic non-small cell lung cancer with anaplastic lymphoma kinase rearrangementsOncologist20141910e5e1125170012
   PubMed Web of Science ®Google Scholar
• DasAChengRRHilbertMLSynergistic effects of crizotinib and temozolomide in experimental FIG-ROS1 fusion-positive glioblastomaCancer Growth Metastasis20158516026648752
   PubMedGoogle Scholar
• KrytskaKRylesHTSanoRCrizotinib synergizes with chemotherapy in preclinical models of neuroblastomaClin Cancer Res201622494896026438783
   PubMed Web of Science ®Google Scholar
• KimHJYoonARyuJYc-MET as a potential therapeutic target in ovarian clear cell carcinomaSci Rep201663850227917934
   PubMedGoogle Scholar
• ZouHYLiQLeeJHAn orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanismsCancer Res20076794408441717483355
   PubMed Web of Science ®Google Scholar
• ZhouWJZhangXChengCCrizotinib (PF-02341066) reverses multidrug resistance in cancer cells by inhibiting the function of P-glycoproteinBr J Pharmacol201216651669168322233293
   PubMed Web of Science ®Google Scholar
• HollidayDLSpeirsVChoosing the right cell line for breast cancer researchBreast Cancer Res201113421521884641
   PubMed Web of Science ®Google Scholar
• RissTLMoravecRANilesALCell viability assaysSittampalamGSCoussensNPNelsonHAssay Guidance ManualBethesda, MDEli Lilly & Company and the National Center for Advancing Translational Sciences2004143
   Google Scholar
• ChouTCTheoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studiesPharmacol Rev200658362168116968952
   PubMed Web of Science ®Google Scholar
• ChouTCDrug combination studies and their synergy quantification using the Chou-Talalay methodCancer Res201070244044620068163
   PubMed Web of Science ®Google Scholar
• TallaridaRJAn overview of drug combination analysis with isobologramsJ Pharmacol Exp Ther200631911716670349
   PubMed Web of Science ®Google Scholar
• TallaridaRJCombination analysisAdv Exp Med Biol201067813313720738015
   PubMed Web of Science ®Google Scholar
• UrruticoecheaASmithIEDowsettMProliferation marker Ki-67 in early breast cancerJ Clin Oncol200523287212722016192605
   PubMed Web of Science ®Google Scholar
• TakeuchiKItoFReceptor tyrosine kinases and targeted cancer therapeuticsBiol Pharm Bull201134121774178022130229
   PubMed Web of Science ®Google Scholar
• ZhuKKongXZhaoDLiangZLuoCc-MET kinase inhibitors: a patent review (2011–2013)Expert Opin Ther Pat201424221723024266843
   PubMed Web of Science ®Google Scholar
• LinklaterESTovarEAEssenburgCJTargeting MET and EGFR crosstalk signaling in triple-negative breast cancersOncotarget2016743699036991527655711
   PubMedGoogle Scholar
• BlumenscheinGRJrMillsGBGonzalez-AnguloAMTargeting the hepatocyte growth factor-cMET axis in cancer therapyJ Clin Oncol201230263287329622869872
   PubMed Web of Science ®Google Scholar
• BoccaccioCComoglioPMMET, a driver of invasive growth and cancer clonal evolution under therapeutic pressureCurr Opin Cell Biol2014319810525305631
   PubMed Web of Science ®Google Scholar
• YanSJiaoXZouHLiKPrognostic significance of c-Met in breast cancer: a meta-analysis of 6010 casesDiagn Pathol2015106226047809
   PubMed Web of Science ®Google Scholar
• KwakELBangYJCamidgeDRAnaplastic lymphoma kinase inhibition in non-small-cell lung cancerN Engl J Med2010363181693170320979469
   PubMed Web of Science ®Google Scholar
• CuiJJTran-DubeMShenHStructure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK)J Med Chem201154186342636321812414
   PubMed Web of Science ®Google Scholar
• GerdesJSchwabULemkeHSteinHProduction of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferationInt J Cancer198331113206339421
   PubMed Web of Science ®Google Scholar
• VeroneseSMGambacortaMGottardiOScanziFFerrariMLamperticoPProliferation index as a prognostic marker in breast cancerCancer19937112392639318508358
   PubMedGoogle Scholar
• MegiorniFMcDowellHPCameroSCrizotinib-induced antitumour activity in human alveolar rhabdomyosarcoma cells is not solely dependent on ALK and MET inhibitionJ Exp Clin Cancer Res20153411226445453
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists’ Collaborative Group (EBCTCG)PetoRDaviesCComparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trialsLancet2012379981443244422152853
   PubMed Web of Science ®Google Scholar
• GogineniKDeMicheleACurrent approaches to the management of Her2-negative metastatic breast cancerBreast Cancer Res201214220522429313
   PubMed Web of Science ®Google Scholar
• YardleyDADrug resistance and the role of combination chemotherapy in improving patient outcomesInt J Breast Cancer2013201313741423864953
   PubMedGoogle Scholar
• Van Der SteenNDebenCDeschoolmeesterVBetter to be alone than in bad company: the antagonistic effect of cisplatin and crizotinib combination therapy in non-small cell lung cancerWorld J Clin Oncol20167642543228008383
   PubMedGoogle Scholar
• RaghavKPGonzalez-AnguloAMBlumenscheinGRJrRole of HGF/MET axis in resistance of lung cancer to contemporary managementTransl Lung Cancer Res20121317919325806180
   PubMedGoogle Scholar
• WangJChengJXc-Met inhibition enhances chemosensitivity of human ovarian cancer cellsClin Exp Pharmacol Physiol2017441798727658187
   PubMedGoogle Scholar
• LiEHuZSunYSmall molecule inhibitor of c-Met (PHA665752) suppresses the growth of ovarian cancer cells and reverses cisplatin resistanceTumour Biol20163767843785226695152
   PubMedGoogle Scholar
• ChenZShiTZhangLMammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: a review of the past decadeCancer Lett2016370115316426499806
   PubMed Web of Science ®Google Scholar
• SaunaZEKimIWAmbudkarSVGenomics and the mechanism of P-glycoprotein (ABCB1)J Bioenerg Biomembr2007395–648148718058211
   PubMed Web of Science ®Google Scholar
• van AmerongenRBernsATXR1-mediated thrombospondin repression: a novel mechanism of resistance to taxanes?Genes Dev200620151975198116882973
   PubMedGoogle Scholar
• LiJLiuJGuoNZhangXReversal of multidrug resistance in breast cancer MCF-7/ADR cells by h-R3-siMDR1-PAMAM complexesInt J Pharm2016511143644527444552
   PubMed Web of Science ®Google Scholar
• SahuAPrabhashKNoronhaVJoshiADesaiSCrizotinib: a comprehensive reviewSouth Asian J Cancer201322919724455567
   PubMedGoogle Scholar
• LawrenceRESalgiaRMET molecular mechanisms and therapies in lung cancerCell Adh Migr20104114615220139696
   PubMed Web of Science ®Google Scholar